Vor Biopharma Inc. — Director's Dealing 2021

Feb 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vor Biopharma Inc. (VOR)
CIK: 0001817229
Period of Report: 2021-02-04

Reporting Person: Jorgensen Nathan D. (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25735	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (3534)		Direct
Employee Stock Option (right to buy)	$1.90	2030-08-24	Common Stock (115578)		Direct
Employee Stock Option (right to buy)	$1.90	2030-08-20	Common Stock (135514)		Direct

Footnotes

F1: Each share of Series B Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 13.6-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: 1/4th of the shares underlying the option vest on May 22, 2021, with the remainder vesting in equal monthly installments over 3 years, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.

F3: 11/48ths of the shares underlying the option vest on June 1, 2021, with the remainder vesting in equal monthly installments over 37 months, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date.